Sputnik V-Induced Antibodies against SARS-CoV-2 Variants during the Dissemination of the Gamma Variant in Venezuela.

Sputnik V-Induced Antibodies against SARS-CoV-2 Variants during the Dissemination of the Gamma Variant in Venezuela.

Publication date: Sep 18, 2024

The COVID-19 pandemic was characterized by the emergence and succession of SARS-CoV-2 variants able to evade the antibody response induced by natural infection and vaccination. To evaluate the IgG reactivity and neutralizing capacity of the serum of individuals vaccinated with Sputnik V (105 volunteers vaccinated) against different viral variants. IgG reactivity to the Spike protein (S) was evaluated by ELISA. A plaque reduction neutralization test was performed using different viral variant isolates. At 42 days post-vaccination, the frequency of recognition and reactivity to the S protein of the Omicron variant was lower compared to that of the other variants. In general, a higher average neutralization titer was seen against the ancestral variant compared to the variants, especially Omicron. However, some sera exhibited a higher neutralization titer to the Gamma variant compared to the ancestral variant, suggesting unapparent exposure during the clinical trial. Antibodies induced by Sputnik V can recognize, persist, and neutralize SARS-CoV-2 variants, with Omicron being the one that best evades this response. These results represent a unique report on the humoral response induced by a globally lesser-studied vaccine in terms of efficacy and immune escape, offering insights into developing vaccines targeting unknown coronaviruses.

Open Access PDF

Concepts Keywords
Antibodies Adult
Coronaviruses antibodies
Unapparent Antibodies, Neutralizing
Venezuela Antibodies, Neutralizing
Volunteers Antibodies, Viral
Antibodies, Viral
COVID-19
COVID-19 Vaccines
COVID-19 Vaccines
ELISA
Female
Humans
Immunoglobulin G
Immunoglobulin G
Male
Middle Aged
neutralization
Neutralization Tests
SARS-CoV-2
SARS-CoV-2
Spike Glycoprotein, Coronavirus
Spike Glycoprotein, Coronavirus
spike protein, SARS-CoV-2
Sputnik V
Vaccination
variants
Venezuela

Semantics

Type Source Name
disease MESH COVID-19 pandemic
disease MESH infection
disease IDO protein
drug DRUGBANK Coenzyme M
disease IDO replication
disease IDO host
disease MESH sequelae
disease IDO country
disease IDO assay
disease IDO process
drug DRUGBANK Carboxymethylcellulose
drug DRUGBANK Formaldehyde
drug DRUGBANK Gentian violet cation
drug DRUGBANK Ademetionine
drug DRUGBANK Aspartame
drug DRUGBANK Esomeprazole

Original Article

(Visited 2 times, 1 visits today)